Points to consider concerning endpoints in clinical studies with haematopoeitic growth factors for mobilisation of autologous stem cells

We have adopted this International Scientific Guideline - CPMP/EWP/197/99

Last updated

17 January 2025

About this guideline

Overseas effective date: 1 September 2000

Categories: Clinical efficacy and safety | Blood and blood-forming organs

TGA annotations: Nil

Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

Product types